Navigation Links
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
Date:11/11/2008

ntestinal permeability-inflammation loop. Larazotide acetate inhibits tight junction opening triggered by both gluten and inflammatory cytokines, thus reducing uptake of gluten. Larazotide acetate disrupts the intestinal permeability-inflammation loop, and reduces symptoms associated with celiac disease. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn's Disease. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat autoimmune and inflammatory diseases and is located in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Media: Mariesa Kemble

Sam Brown Communications

608-850-4745

kemblem@aol.com

Corporate: Wendy Perrow, MBA

Alba Therapeutics Corporation

410-878-9850

info@albatherapeutics.com

http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
3. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
6. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
7. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
8. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
9. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. Browse the full ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/11/2014)... Children who have emergency surgery on weekends are ... death than those who have weekday surgeries, according ... Hopkins researchers noted that the risk of death ... nearly 440,000 simple emergency surgeries that children across ... The surgeries are considered generally safe and ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... Miriam Hospital have found that people with mobility ... of smoking than those without mobility impairments. Additionally, ... attempt quitting than those without mobility impairments, and ... this population. The study and its findings are ... American Journal of Public Health . ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... children from the worldwide scourge of dengue fever was somewhat ... vaccine only prevented dengue fever in 56 percent of the ... it protected more than 88 percent of them from severe ... hospitalization, and sometimes death. "This vaccine has already proven ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... Could be targets for new treatments, researchers say , FRIDAY, ... genetic variants associated with high blood pressure in black Americans ... treat this major risk factor for heart disease and stroke. ... of PLoS Genetics , is one of a series ...
... , , , PLAINVIEW, N.Y., ... that its 2009 community outreach program has already provided more than ... Free services, including vision screenings, eye exams and eyeglasses have been ... , "We bring our ,Focus on America, ...
... ... Diprivan (Propofol) abuse , the Farley Center at Williamsburg Place, one of the nation,s leading ... ... -- In response to the recent media attention on Diprivan (Propofol) abuse , the ...
... WORCESTER, Mass., July 17 The Hanover Insurance Group (NYSE: ... today announced the availability of a new product offering that can extend ... , , (Logo: ... The coverage is more important than ever as the population of ...
... , , , WINSTON-SALEM, N.C., ... vice president for finance and chief financial officer of Wake Forest ... the Medical Center reorganization that began two years ago. He began ... CEO of the Medical Center. , , ...
... , , SKILLMAN, N.J., July ... technologies for community and hospital care, announced today it received first ... Advertising Effectiveness Awards for its Flexi-Seal((R) )Fecal Management System (FMS). ... Flexi-Seal((R)) FMS, a temporary containment device for patients with acute fecal ...
Cached Medicine News:Health News:Five Hypertension Genes Found in Black Americans 2Health News:Five Hypertension Genes Found in Black Americans 3Health News:Davis Vision Provides More Than $200,000 in Free Vision Care Services 2Health News:Davis Vision Provides More Than $200,000 in Free Vision Care Services 3Health News:Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse 2Health News:Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse 3Health News:Omar S. Manejwala, MD Speaks Out Nationally on Diprivan/Propofol Abuse 4Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 3Health News:Wake Forest Baptist Medical Center Names Chadwick CFO 2Health News:Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award 2Health News:Flexi-Seal(R) Fecal Management System Receives 2008 Critical Care Nurse Advertising Effectiveness Award 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: